Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:cyclosporine
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinical_trial |
studied for autoimmune diseases
studied for heart transplant patients studied for kidney transplant patients studied for liver transplant patients |
| gptkbp:contraindication |
hypersensitivity to cyclosporine
concurrent use of certain nephrotoxic drugs |
| gptkbp:dosage_form |
oral solution
soft gelatin capsule |
| gptkbp:formulation |
gptkb:beer
gptkb:software_framework |
| https://www.w3.org/2000/01/rdf-schema#label |
Sandimmune
|
| gptkbp:indication |
gptkb:rheumatoid_arthritis
psoriasis atopic dermatitis |
| gptkbp:ingredients |
gptkb:cyclosporine
|
| gptkbp:interacts_with |
may interact with certain antibiotics
may interact with antifungal medications may interact with grapefruit juice |
| gptkbp:invention |
patented
off-patent |
| gptkbp:is_available_on |
gptkb:brand
generic version |
| gptkbp:is_monitored_by |
blood pressure monitoring required
drug level monitoring recommended renal function monitoring required |
| gptkbp:is_used_for |
preventing organ transplant rejection
|
| gptkbp:lifespan |
approximately 19 hours
|
| gptkbp:manager |
oral
intravenous |
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
metabolized by CY P3 A4
|
| gptkbp:price |
varies by region
covered by insurance plans |
| gptkbp:requires |
prescription only
|
| gptkbp:research_focus |
immunology
autoimmune disorders transplantation medicine |
| gptkbp:safety_features |
Category C in pregnancy
not recommended during breastfeeding |
| gptkbp:side_effect |
high blood pressure
tremors neurotoxicity hepatotoxicity hyperkalemia nephrotoxicity kidney dysfunction increased risk of infection gum hyperplasia |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:symptoms |
flare of autoimmune disease
rebound organ rejection |